CTOs on the Move

Lenox Hill Hospital

www.lenoxhillhospital.org

 
Lenox Hill Hospital, a member of the North Shore-LIJ Health System, is a 652-bed, fully accredited, acute care hospital located on Manhattan’s Upper East Side with a national reputation for outstanding patient care and innovative medical and surgical treatments. US News and World Report has ranked the hospital among the nation’s top 50 in Cardiology and Heart Surgery and among the top 10 hospitals in the state of New York with a total of 11 “high performing” designations for its clinical performance in Cancer, Diabetes and Endocrinology, Ear, Nose and Throat, Gastroenterology and GI Surgery, Geriatrics, Gynecology, Nephrology, Neurology and ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Virun

Virun is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Walnut, CA. To find more information about Virun, please visit www.virun.com

Canadian Dental Service Plans

Canadian Dental Service Plans Inc. is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kind and Total Health System

Kind and Total Health System is a Alhambra, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Care Products Inc

Care Products Inc is a Waterbury, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.